SEP-786 is an oral small molecule agonist of the parathyroid hormone 1 receptor (PTH1R) being developed for the treatment of hypoparathyroidism. Septerna’s decision follows the observation of ...
Septerna (SEPN) announced its decision to discontinue the Phase 1 single- and multiple-ascending dose clinical trial of SEP-786 in healthy volunteers. SEP-786 is an oral small molecule agonist of ...
JOHOR BAHRU-A RM2.6 billion (S$788 million) development including a mall topped by four towers is being planned at the Johor Bahru terminus of the upcoming Johor Bahru-Singapore Rapid Transit ...
The RM2.6 billion (S$786 million) development is a strategic partnership between Malaysia's Mass Rapid Transit Corporation (MRT Corp) and Malaysian conglomerate Sunway Group. Both parties signed ...